Glycine transporter inhibitors

[1]  D. Curtis.  A possible role for sarcosine in the management of schizophrenia , 2019, British Journal of Psychiatry.

[2]  A. Wysokiński,et al.  Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study) , 2018, Psychiatry Research.

[3]  D. Javitt,et al.  Targeting glutamate to treat schizophrenia: lessons from recent clinical studies , 2016, Psychopharmacology.

[4]  Yue-Cune Chang,et al.  Inhibition of Glycine Transporter-I as a Novel Mechanism for the Treatment of Depression , 2013, Biological Psychiatry.

[5]  H. Lane,et al.  Sarcosine Therapy for Obsessive Compulsive Disorder: A Prospective, Open-Label Study , 2011, Journal of clinical psychopharmacology.

[6]  P. Wlaź,et al.  Effects of sarcosine, a glycine transporter type 1 inhibitor, in two mouse seizure models , 2010, Pharmacological reports : PR.

[7]  M. V. Centeno,et al.  Prefrontal cortex and spinal cord mediated anti-neuropathy and analgesia induced by sarcosine, a glycine-T1 transporter inhibitor , 2009, PAIN®.

[8]  B. Söderpalm,et al.  The glycine reuptake inhibitor Org 25935 decreases ethanol intake and preference in male wistar rats. , 2006, Alcohol and alcoholism.

[9]  B. Yee,et al.  Pharmacotherapy Through the Inhibition of Glycine Transporters: An Update on and Beyond Schizophrenia , 2017 .

[10]  D. Javitt,et al.  Safety, tolerability and pharmacokinetics of open label sarcosine added on to anti-psychotic treatment in schizophrenia - preliminary study. , 2015, The Israel journal of psychiatry and related sciences.